Condition: Treatment-resistant Depression (TRD) · Sponsor: Alto Neuroscience
The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD.
This description comes directly from the study's public registry record.
Alto Neuroscience · 650-200-0412 · clinical@altoneuroscience.com
Always discuss trial participation with your own doctor first.
| Site 7074 | Birmingham, Alabama, United States | Not Yet Recruiting |
| Site 7173 | Dothan, Alabama, United States | Not Yet Recruiting |
| Site 7000 | Phoenix, Arizona, United States | Recruiting |
| Site 7153 | Chino, California, United States | Not Yet Recruiting |
| Site 7156 | Oakland, California, United States | Not Yet Recruiting |
| Site 7082 | Oceanside, California, United States | Recruiting |
| Site 7159 | Palo Alto, California, United States | Not Yet Recruiting |
| Site 7016 | Sacramento, California, United States | Not Yet Recruiting |
| Site 7144 | San Diego, California, United States | Recruiting |
| Site 7171 | Valley Village, California, United States | Not Yet Recruiting |
| Site 7152 | Saint Augustine, Florida, United States | Recruiting |
| Site 7148 | Albany, Georgia, United States | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07553637